Related Experiment Video

Updated: Jun 2, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

[Remarkable results with candesartan]

Frans H Rutten1, Rolf H H Groenwold

  • 1Universitair Medisch Centrum Utrecht, Julius Centrum voor Gezondheidswetenschappen en Eerstelijns Geneeskunde, Utrecht, the Netherlands. f.h.rutten@umcutrecht.nl

Nederlands Tijdschrift Voor Geneeskunde
|April 21, 2011
PubMed

Insights

Candesartan use was linked to lower mortality in heart failure patients compared to losartan. However, this observational study

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Research

Background:

  • Heart failure (HF) management involves various medications, including angiotensin receptor blockers (ARBs).
  • Observational studies comparing ARBs like candesartan and losartan in HF populations can provide real-world insights.
  • Previous randomized controlled trials (RCTs) have established the efficacy of ARBs in HF.

Purpose of the Study:

  • To comment on an observational study comparing candesartan and losartan in patients with heart failure.
  • To critically evaluate the methodology and potential biases of the original study.
  • To discuss implications for clinical practice and future research.

Main Methods:

  • Critical analysis of an observational study involving 30,254 Swedish heart failure patients.
  • Review of propensity score methods used for confounding adjustment.
  • Assessment of potential biases including drug adherence, dosage equivalence, and loss-to-follow-up.

Main Results:

  • The original study suggested candesartan was associated with lower all-cause mortality than losartan (HR 0.70).
  • The authors of the comment argue this finding may be confounded by non-equipotential dosages and differential drug adherence.
  • Selective loss-to-follow-up was also identified as a potential source of bias.

Conclusions:

  • The observational study's findings should not alter current clinical practice for heart failure management.
  • Methodological limitations, including non-equipotential dosing and adherence issues, may explain the observed mortality difference.
  • Head-to-head comparisons of ARBs should ideally be conducted in randomized controlled trials with equipotential dosages.

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...